Coronavirus reinfections: three questions scientists are asking.

@article{Ledford2020CoronavirusRT,
  title={Coronavirus reinfections: three questions scientists are asking.},
  author={Heidi Ledford},
  journal={Nature},
  year={2020}
}
Second infections raise questions about long-term immunity to COVID-19 and the prospects for a vaccine. Second infections raise questions about long-term immunity to COVID-19 and the prospects for a vaccine. 
Lessons From Bacille Calmette-Guérin for SARS-CoV-2 Vaccine Candidates
Abstract Developers of severe acute respiratory syndrome coronavirus 2 vaccines should consider some of the lessons from a “new” vaccine introduced in 1921, namely bacille Calmette-Guérin.
Immunology of COVID-19.
  • H. Brüssow
  • Biology, Medicine
  • Environmental microbiology
  • 2020
TLDR
Recent research literature on immune aspects of COVID-19 is summarized in this review with an outlook how bats have evolved to live with these viral infections. Expand
Lessons from BCG for SARS-CoV-2 vaccine candidates.
TLDR
Developers of SARS-CoV-2 vaccines should consider some of the lessons from a 'new' vaccine introduced in 1921, namely BCG, according to the World Health Organization. Expand
Antibody Responses in COVID-19: A Review
TLDR
Cellular immunity seems to be crucial in the resolution of the infection, as SARS-CoV-2-specific CD4+ and CD8+ T cells circulate to some extent in recovered patients, but the duration of the antibody response has not been well established yet. Expand
One dose of COVID-19 nanoparticle vaccine REVC-128 protects against SARS-CoV-2 challenge at two weeks post-immunization
  • Maggie Gu, Jonathan L Torres, +11 authors Yimeng Wang
  • Medicine
  • Emerging microbes & infections
  • 2021
TLDR
In-vivo immunogenicity evaluation in mice indicates that a single dose of this vaccine induces potent serum neutralizing antibody titre at two weeks post-immunization, which suggests that the REVC-128 is a safe, stable and efficacious single-shot vaccine to give the earliest protection against SARS-CoV-2 infection. Expand
One dose of COVID-19 nanoparticle vaccine REVC-128 provides protection against SARS-CoV-2 challenge at two weeks post immunization
TLDR
In-vivo immunogenicity evaluation in mice indicates that a single dose of this vaccine induces potent serum neutralizing antibody titer at two weeks post immunization, which is significantly higher than titer induced by trimeric spike protein without nanoparticle presentation. Expand
SARS-CoV-2 structural features may explain limited neutralizing-antibody responses
TLDR
It is proposed here that coronaviruses employ a structural strategy to avoid strong and enduring antibody responses, offering an explanation for the inefficient and short-lived neutralizing antibody responses of SARS-CoV-2-infected patients. Expand
SARS-CoV-2 antibodies in breastmilk after COVID-19 and/or vaccination
Several studies to date show that most people who have been infected with SARS-CoV-2 or vaccinated develop antibodies specific to this virus. However, the levels of these antibodies can vary betweenExpand
Antibody indexes in COVID-19 convalescent plasma donors: Unanswered questions
TLDR
The study showed an association between higher antibody indexes and severe COVID-19 cases, and several hypotheses regarding the association of the antibody dynamics and severity of the disease in SARS-CoV-2 infection have been raised, although many questions remain unanswered. Expand
The peripheral T cell population is associated with pneumonia severity in cynomolgus monkeys experimentally infected with severe acute respiratory syndrome coronavirus 2
TLDR
The data suggest that the peripheral T lymphocyte population is associated with pneumonia severity in cynomolgus monkeys experimentally infected with SARS-CoV-2, and will increase the understanding of disease pathogenesis and may facilitate the development of animal models for vaccine evaluation. Expand
...
1
2
3
4
...

References

SHOWING 1-3 OF 3 REFERENCES
Genomic Evidence for a Case of Reinfection with SARS-CoV-2
TLDR
It is concluded that it is possible for humans to become infected multiple times by SARS-CoV-2, but the generalizability of this finding is not known. Expand
COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing
  • K. To, I. Hung, +17 authors K. Yuen
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2020
TLDR
The results suggest SARS-CoV-2 may continue to circulate among the human populations despite herd immunity due to natural infection or vaccination, and further studies of patients with re-infection will shed light on protective correlates important for vaccine design. Expand
  • SSRN
  • 2020